Text Size
1 study found for:    OSI-906-207

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Conditions: Non Small Cell Lung Cancer;   NSCLC
Interventions: Drug: OSI-906;   Drug: Erlotinib;   Drug: Placebo
To Top

† Indicates status has not been verified in more than two years